Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Jason Stubbs, MD
Collaborators
NCT06422871 · End Stage Renal Disease, Hemodialysis Access Failure
NCT06326905 · Quality of Life, Depression, and more
NCT07157397 · End Stage Renal Disease (ESRD), End Stage Kidney Disease (ESRD), and more
NCT07020832 · Delayed Graft Function, End Stage Renal Disease, and more
NCT05726526 · Chronic Kidney Disease Stage 5, End Stage Renal Disease
University of Kansas Medical Center
Kansas City, Kansas
Westwood Dialysis Center
Westwood, Kansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions